Vitamin B3-related NAD+ precursor · Fact sheet

Nicotinamide riboside

Also known as NR · niagen

Nicotinamide riboside can raise NAD-related biomarkers in people, but it is not an FDA-approved drug for aging, cognitive decline, mitochondrial disease, or fatigue. Biomarker movement should not be confused with proven health benefit.

Not FDA approvedEarly human evidence

What is Nicotinamide riboside?

Nicotinamide riboside is a vitamin B3-related compound and one of several precursors cells can use to make NAD+.

It is sold in dietary supplements, a category FDA does not approve for safety and effectiveness before marketing.

Benefits & claims

NR offers an oral way to influence NAD metabolism without administering NAD+ itself.

It is studied across metabolic, cardiovascular, muscle, neurological, and aging-related questions, but small trials and multiple endpoints make isolated positive signals easy to overinterpret.

What the evidence supports

  • Trials commonly report increased blood NAD-related metabolites.
  • A randomized pilot in mild cognitive impairment found target engagement but did not show a significant cognitive benefit over placebo.
Research areas
  • NAD+ metabolism
  • Mild cognitive impairment
  • Cardiometabolic and vascular outcomes
  • Muscle and mitochondrial function

Dosage & frequency

Human study context

Nicotinamide riboside can raise NAD-related biomarkers in human studies. Those changes do not establish a clinical anti-aging treatment dose.

Randomized NR metabolic study

40 sedentary men age 40–70 with obesity and insulin resistance

Amount
1,000 mg per dose
Frequency
Twice daily for twelve weeks
Route studied or labeled
Oral

Insulin sensitivity and body composition did not improve; not a recommended metabolic regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Nicotinamide riboside chloride is distinct from NMN and direct NAD+.
  • A GRAS food-ingredient assessment is not FDA drug approval for treating disease.

Interactions & precautions

  • The cited metabolic trial is not a comprehensive drug-interaction study; biomarker increases do not establish combination safety.

What is still unresolved

  • Meaningful cognitive, physical-function, and longevity benefits remain uncertain.

Side effects & risks

  • Short controlled studies generally report acceptable tolerability, but they are not large or long enough to define uncommon harms.
  • Supplement strength, purity, and labeling can vary, and FDA does not preapprove supplements for effectiveness.
  • Long-term consequences of chronically altering NAD metabolism in diverse populations are uncertain.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Multiple human trials establish absorption and biomarker effects. Controlled studies have not yet established a durable, reproducible benefit on cognition, physical function, or major clinical outcomes.

Studies

What do the human studies show?

Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.

Who took part, what was measured, and what the study found
Study and peopleQuestion and follow-upResult and limits
NR mild cognitive impairment pilot

Older adults with mild cognitive impairment

20 participants (actual)

Randomized placebo-controlled trial; human

Nicotinamide riboside versus Placebo

10 weeks

Primary: Change in Montreal Cognitive Assessment score

DNA methylation; secondary blood NAD+ and other functional measures.

Phase: Not listed in this summary
Registry status: Not assessed
Registry results: Not assessed
Publication: published; peer reviewed

Blood NAD+ increased; cognition did not change.

Cannot tell us: Too small and short to establish prevention of dementia or rare harms. Cerebral blood-flow findings did not survive correction for multiple comparisons.

Safety, uncertainty, and source details

No between-group difference in reported adverse events in this small pilot.

Limited to the studied population, formulation and follow-up.

Funding/conflicts: Not confirmed in this summary; check the full paper.

Source checked: 2026-09-18. Independent clinical review: not completed.

What these results can and cannot tell us

Did higher blood NAD+ improve cognition in the NR pilot?

Biomarker change occurred without a demonstrated cognitive improvement in this pilot.

Limit: A biomarker increase does not itself establish patient benefit or dementia prevention.

Check the sources: Nicotinamide riboside pilot in mild cognitive impairment (checked 2026-09-18)

Related, not equivalent: NAD+ · Nicotinamide mononucleotide.

Compare research questions · Submit a source-based correction

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

More energy with shorter sleep

A 49-year-old man reported stronger workouts, clearer thinking and better mood over six weeks, but shorter sleep and vivid dreams. His supplement also contained resveratrol, quercetin and fisetin.

Reported use in this account

Product
Nicotinamide-riboside chloride supplement with other ingredients
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Six weeks at the report

Other exposures described: Resveratrol, quercetin and fisetin in the same supplement; Changing workload, diet and exercise

The combination, workload and inconsistent diet and exercise prevent attribution to NR alone. Feeling energized is not a measure of NAD levels or longevity.

Read the original account
Mixed account · personal report

Daytime energy with unusually memorable dreams

A separate 37-year-old commenter reported more energy and concentration, no difficulty falling asleep, and unusually intense, memorable dreams. Their follow-up identified an NR amount, while also describing GlyNAC, PABA and some NMN use.

Reported use in this account

Product
NR capsules
Amount
300 mg in two capsules, as reported
Frequency
Daily in the morning
Route
Oral capsules taken with water
Duration
A couple of years across NR or NMN use; NR-only duration not stated

Other exposures described: GlyNAC; PABA; NMN used during the broader period; Workload, family changes, diet and exercise

The other supplements, intermittent NMN use and lifestyle factors prevent attribution to NR. The report does not verify NAD levels, skin-disease treatment or an anti-aging effect.

Read the separate account and its amount clarification

Approval status

No nicotinamide-riboside drug is FDA approved to prevent or treat aging, cognitive decline, mitochondrial dysfunction, or fatigue. Dietary-supplement marketing does not equal FDA approval.

Supplement and food-ingredient status, not drug approval

Nicotinamide riboside has human biomarker trials and food-ingredient regulatory material, but no FDA-approved drug use for aging, cognition, fatigue, or disease treatment.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether any biomarker change improves healthspan or disease outcomes
  • Whether a specific deficient or disease-defined population benefits
  • Long-term safety and clinically meaningful interactions
  • How NR compares with NMN or lifestyle interventions on patient-centered outcomes

Summary

NR raises NAD-related biomarkers. Consistent benefits for memory, energy or longevity have not been established.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedRandomized NR pilot in mild cognitive impairment

    Placebo-controlled pilot reporting biomarker engagement without a significant cognitive benefit.

  2. pubmedSystematic review of NAD precursor trials

    Review of human NR and NMN trials describing consistent biomarker effects and heterogeneous clinical outcomes.

  3. fdaFDA GRAS notice response materials for NR chloride

    Food-ingredient regulatory record; GRAS status is not approval of anti-aging or disease claims.

  4. fdaFDA: what ‘FDA approved’ does and does not mean

    FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.

  5. pubmedRandomized NR trial in obese insulin-resistant men

    Primary source for the practical reference information.

How we assess sources · Suggest a correction